Status: Recruiting
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients. Most hospitals prescribe valganciclovir for this purpose but valacyclovir has also been used. The most unfavorable side effect of valganciclovir is bone marrow suppression which can be troublesome for kidney transplant patients who are already immunosuppressed. We aim to assess the non-inferiority of valacyclovir compared with valganciclovir in this study.
Participants needed: 80
Trial details
Age: 3+Biological sex: AllType: InterventionalSponsor: National Taiwan University HospitalUpdated: Dec 19, 2025Locations: 1
Eligibility criteria
Age at least 3 years of age [+4]
Severe co-morbidities that would preclude safe participation as judged by the tr... [+2]